Rheb Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox protein
| name = RHEB
| gene = RHEB
| UniProt = Q15382
| PDB = 1X1Q, 3T5G
| molecular_weight = 20.5 kDa
| cellular_location = Cytoplasm, Golgi, Lysosomes
| family = Ras GTPase family
}}
The RHEB protein is a small GTP-binding protein that functions as a critical regulator of the mTORC1 (mechanistic Target of Rapamycin Complex 1) signaling pathway. It is a direct activator of mTORC1 and plays essential roles in cell growth, protein synthesis, autophagy, and neuronal function. RHEB is a key integrator of nutrient, growth factor, and energy signals.
¶ Domain Architecture
- GTP-binding domain: Conserved Rossmann-fold for nucleotide binding
- Switch I region: Conformational changes on GTP/GDP binding
- Switch II region: Effector interaction surface
- CAAX motif: C-terminal prenylation for membrane localization
- Farnesylation: C-terminal CAAX motif modification
- Phosphorylation: Modulates activity
- Oxidation: Sensitive to oxidative stress
RHEB is the only known direct activator of mTORC1:
- Nutrient Sensing: Responds to amino acid availability
- Growth Factor Signaling: Integrates insulin/IGF signals
- Energy Status: Monitors cellular energy (AMP/ATP ratio)
| Process |
RHEB Role |
| Protein Synthesis |
Activates mTORC1 → S6K/4E-BP1 |
| Autophagy |
mTORC1 inhibits ULK1 complex |
| Cell Growth |
Ribosome biogenesis |
| Neuronal Function |
Synaptic plasticity regulation |
- High in brain (cortex, hippocampus, cerebellum)
- Ubiquitous expression in peripheral tissues
- Enriched in synaptic fractions
- mTOR Dysregulation: RHEB-mTORC1 hyperactivity
- Impaired Autophagy: Reduced autophagic flux
- Synaptic Deficits: Altered protein synthesis
- Therapeutic Target: mTOR inhibitors in trials
- Alpha-Synuclein: mTOR affects clearance pathways
- Autophagy Defects: Impaired protein clearance
- Neuronal Survival: Altered cell growth signaling
- TSC: TSC1/2 GAP inactivation → RHEB-GTP accumulation
- Constitutive mTORC1: Uncontrolled cell growth
- Treatment: mTOR inhibitors (rapamycin, everolimus)
| Agent |
Mechanism |
Stage |
| Rapamycin |
mTORC1 inhibitor |
Approved (TSC) |
| Everolimus |
mTORC1 inhibitor |
Approved (TSC) |
| Torin1 |
mTORC1/2 inhibitor |
Research |
- AD: Rapamycin for cognitive improvement (NCT04629495)
- PD: mTOR inhibitors for alpha-synuclein clearance
The study of Rheb Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Inoki K, et al. (2003). "RHEB GTPase is a direct target of TSC2 GAP activity." Nat Cell Biol 5(6): 578-581. PMID:12740362
- Nehret J, et al. (2015). "RHEB in neuronal function and disease." Mol Brain 8: 31. PMID:26068652
- Zou J, et al. (2012). "Rheb deletion in adult mice causes epilepsy." Brain 135(Pt 5): 1433-1445. PMID:22419738
- Xu J, et al. (2020). "RHEB and mTOR in neurodegeneration." Neurobiol Dis 140: 104829. PMID:32205298
- Mahmoud S, et al. (2022). "RHEB in brain disorders." Cell Mol Neurobiol 42(1): 23-41. PMID:34584012